Resources

Resource centre

Scientific Posters

AAPS 2022 Poster: Formulation and Taste Assessments in First in Human Studies

Quotient Sciences AAPS 2022 Poster, "Formulation and Taste Assessments in First in Human Studies"

Streamlining the Delivery of 14C Human ADME Data: An ADME Q&A Roundtable

On December 6, 2022, join Quotient Sciences and The Netherlands Organization for Applied Scientific Research (TNO) for an interactive, hour-long live Q&A webinar focused on streamlining human ADME studies.

Scientific Posters

AAPS 2022 Poster: Kilo Scale Synthesis in Daisy Chained Flow Reactors

Quotient Sciences AAPS 2022 Poster, "Kilo Scale Synthesis in Daisy Chained Flow Reactors." (2R, 6R) hydroxynorketamine is a pharmaceutical undergoing trials as an antidepressant. An atom efficient synthesis route with norketamine as an intermediate is known. A low throughput flow synthesis route to norketamine had previously been developed, 2 however a manufacturing scale method was required. The objective of this study is to conduct the entire synthesis of norketamine from 2 chlorophenylcyclopentyl ketone in daisy chained reactors, built mainly from readily available parts at a throughput of > 1 kg/day.

Quotient Sciences Aseptic Development & Manufacturing Capabilities Info Sheet

Quotient Sciences has expertise in developing, manufacturing, testing, releasing, and supplying a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies.

Quotient Sciences and Charles River Collaboration Info Sheet

Learn more about the collaboration between Quotient Sciences and Charles River.

Scientific Posters

A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers.

"A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers." The poster was presented at the Pharmacology 2022 conference and was co-authored with our customer, Galmed Pharmaceuticals

Scientific Posters

BPS 2022 Poster - A Phase 1 Randomized PK Study of Amilo-5MER

A Phase 1, Randomized, Double-Blind, PlaceboControlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers

Scientific Posters

Assessment of the Contribution of CYP2D6 to the Elimination of Idalopirdine as well as the Absolute Bioavailability Following Multiple Oral Dosing

This study assessed the contribution of CYP2D6 to the metabolization of idalopirdine by comparing pharmacokinetics in CYP2D6 extensive metabolizers (EM) and poor metabolizers (PM) following multiple oral dosing. Comparison of pharmacokinetic (PK) parameters in PMs and EMs may substitute for an interaction study of the effect of CYP2D6 inhibition

Peptide Development Strategies

Peptide drug products continue to gain popularity in the pharmaceutical industry due to their high selectivity, high potency, and good safety profile. However, formulating peptides can present many challenges for drug developers because of their unique physicochemical properties.

Scientific Posters

Applications of Lipid-based Formulations and the Benefits of Integrating Manufacturing and Clinical Testing in Formulation Selection

The purpose of this study is to analyze pharmaceutical and clinical data from multiple development programs to understand the drivers and outcomes of selecting and dosing different lipid formulations.

Peer Reviewed Publication

CC-99677, A Novel, Oral, Selective Covalent MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production

Dr. Stuart Mair, Global Vice President, Medical, Early Development, has contributed to a scientific article on Arthritis Research & Therapy. Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines.

Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms

Watch this webinar featuring Dr. Vanessa Zann, Senior Drug Development Consultant, to learn more about the specialized formulation technologies used to optimize modified release formulation compositions.

Modified-Release Formulation Strategies

With over 30 years of formulation expertise and over 100 MR programs developed, the team at Quotient Sciences possess the experience, capabilities, and technologies needed to create a successful MR formulation.